https://interactions.guidetherapeutiquevih.com/en/interaction-details?id=10009

Rilpivirine

Omeprazole

Contraindicated when taken orally.

No pharmaceutical opinion available for this interaction.

Mechanism

Omeprazole by increasing gastric pH may decrease the solubility, absorption, and plasma concentration of Rilpivirine.

Rilpivirine

Pharmacodynamic effects

Possible decrease of clinical efficacy and risk of possible development of resistance to antiretroviral class.

Recommendations

Avoid association.

Cabenuva : No anticipated interaction so no adjustments necessary.

Alternative solution(s)

–

Omeprazole

Pharmacodynamic effects

–

Recommendations

Contraindicated. Use alternative.

Alternative solution(s)

See rilpivirine + famotidine and rilpivirine + antacids.

Monitor

–

Tests

–

Pharmacokinetic parameters
Parameters
Reference number
# patients
HIV
Dose
Frequency
AUC
Cmax
Cmin
Rilpivirine
3555
16
-
150 mg *
QD
- 40 %
- 40 %
- 33 %
Omeprazole
3555
15
-
20 mg
QD
- 14%
- 14%
 
Comment

Ref #3555 : * The Interaction study has been performed with a dose higher than the recommended dose (25 mg QD) assessing the maximal effect on the coadministered drug.

Reference
  • 3555
    Crauwels HM, van Heeswijk RPG, Kestens D, Stevens M, Buelens A, et al. The pharmacokinetic interaction between omeprazole and TMC278, a next generation non-nucleoside reverse transcriptase inhibitor. 9th International Congress on Drug Therapy in HIV Infection, Glasgow, 9-13 November 2008, abstract P239.
  • 2841
    Rilpivirine (Edurant), Janssen, Ontario, Canada, 20 janvier 2023.
  • 2587
    Emtricitabine/Rilpivirine/Ténofovir DF (Complera), Gilead, Ontario, Canada, 17 octobre 2019.
  • 3441
    Dolutegravir/Rilpivirine (Juluca), ViiV Soins de santé ULC, Quebec, Canada, 5 juillet 2023.
  • 3460
    Rilpivirine/Emtricitabine/Tenofovir alafenamide (Odefsey), Gilead Sciences, Ontario, Canada, 13 novembre 2019.